In melanoma, fibrosarcoma, colon cancer and leukemia models, the co-blocking of TIM-3 and PD-1 showed higher anti-tumor efficacy, more complete tumor regression and longer survival period29,33,34. Here, HAVCR2 is linked to fibrosarcoma.